Loading
A phase 1/2 trial of Pembrolizumab in cervical cancer, run by Qurient Co., Ltd., active and no longer recruiting.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05438420 by Qurient Co., Ltd., with 120 participants planned, started 2023-01-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: Q702, Pembrolizumab. Conditions listed: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/